iPS Cells & Regenerative Medicine– category –
-
Analysis Group Study: Early CAR-T Therapy Ciltacabtagene Autoleucel Achieves 98.0% Overall Response Rate with Favorable Real-World Outcomes in Relapsed/Refractory Multiple Myeloma
Analysis Group USA Overview An Analysis Group study revealed that early-line CAR-T cell therapy, ciltacabtagene autoleucel (cilta-cel), demonstrated favorable real-world outcomes in relapsed or refractory multiple myeloma (RRMM) patients... -
Catalent Expands AAV Gene Therapy Partnership with Taysha Gene Therapies, Securing Exclusive Commercial Manufacturing for Rett Syndrome Treatment TSHA-102
Pharma Manufacturing USA Overview Taysha Gene Therapies and CDMO Catalent have expanded their strategic partnership, designating Catalent as the exclusive commercial manufacturer for TSHA-102, an AAV-based gene therapy for Rett syndrome,... -
RoosterBio and Applied StemCell Partner to Scale iPSC-Based Bioprocess Solutions, Accelerating Cell Therapy Manufacturing
MD Tech Council (Facebook) USA Overview RoosterBio and Applied StemCell have formed a strategic partnership to scale iPSC-based bioprocess solutions, aiming to accelerate the commercial production of cell therapies. This collaboration in... -
ImmunoAct’s NexCAR19 Achieves 98% MRD Negativity in India with Significant Cost Reduction Compared to Western CAR-T Therapies
Citeline Scrip India Overview ImmunoAct's CAR-T cell therapy, NexCAR19 (talicabtagene autoleucel), achieved a 98% minimal residual disease (MRD) negativity rate in real-world Indian data, delivering comparable efficacy to Western CAR-T t... -
Real-World Data Reveals 83.9% Treatment Failure Rate in Second-Line Diffuse Large B-Cell Lymphoma Despite New Therapies; CAR-T Patients Show 26.4-Month Median OS
MDNewsline Unknown Overview Despite the introduction of novel therapies, real-world treatment patterns for Diffuse Large B-Cell Lymphoma (DLBCL) continue to face challenges with poor patient prognosis and high treatment failure rates in ... -
Vertex Pharmaceuticals Secures FDA IND Approval for iPSC-Derived Type 1 Diabetes Therapies, Boosts 2026 Revenue Forecast
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced robust Q2 2026 financial results and significantly raised its full-year revenue guidance, propelled by key pipeline advancements. The company secured FDA Investigationa... -
EUDA Health Partners with GO POSB and SIIT to Accelerate Off-the-Shelf iPSC Cell Therapy for Oncology and Wellness
Stock Titan Singapore Overview EUDA Health announced a collaboration to integrate GO POSB's iPSC platform with SIIT's NK and NK-TCR cell engineering capabilities, aiming to advance off-the-shelf cell therapy programs in oncology and well... -
IMBIOORG2026 Conference Highlights Latest Trends and Partnerships in 3D Bioprinting and Organ Regeneration
InSciTech Summits International Overview The IMBIOORG2026 international conference will showcase cutting-edge research, innovations, and transformative applications in 3D bioprinting, tissue engineering, regenerative medicine, and organ ... -
Advancements in Cell and Gene Therapy Manufacturing: Automation, Cost Reduction, and Scalability Revolutionize Patient Access
Bioprocessing Summit Europe International Overview The cell and gene therapy (CGT) manufacturing sector faces significant operational challenges, including high costs and scalability constraints, particularly due to raw material variabil... -
Allogeneic CAR T-Cells: The Off-the-Shelf Revolution in Cancer Immunotherapy Manufacturing
Liv Hospital Turkey Overview Autologous CAR T-cell therapies face significant hurdles in scalability and turnaround time, limiting their broad accessibility. The industry is rapidly shifting towards off-the-shelf allogeneic CAR T-cells, ...
